Geoffrey Porges

Geoffrey Porges Recent News

AstraZeneca Analyst Flags Lack Of Details In Interim COVID-19 Vaccine Data
AstraZeneca plc (NASDAQ: AZN) announced Monday interim Phase 3 data for its coronavirus vaccine candidate AZD1222 from studies conducted in the U.K.
Pfizer Analysts Raise Odds Of Success For Coronavirus Vaccine Candidate To 100%
Pfizer Inc. (NYSE: PFE) reported Monday with strong Phase 3 interim efficacy data for its coronavirus vaccine candidate.
Pfizer's COVID-19 Vaccine Candidate Primed For $3.5B In 2021 Sales: Analyst
The mRNA coronavirus vaccine in development by Pfizer Inc.
Moderna, Pfizer Have 2-Month Lead Over Coronavirus Vaccine Competitors: Analyst
The coronavirus vaccine race has two likely winners that have surged ahead in a crowded field, according to an SVB Leerink analyst.
Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc.
Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity
Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts
Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential
Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance.
Moderna Looking To Price Its Coronavirus Vaccine At $50-$60, Significantly Above Rivals: FT
Moderna Inc (NASDAQ: MRNA) is looking to price its COVID-19 vaccine significantly ahead of rivals in between $50 and $60 per course, the Financial Times reported Wednesday.
Moderna Analysts See Positives In Coronavirus Readout As Focus Shifts To Pivotal Phase 3 Study
Moderna Inc (NASDAQ: MRNA) shares awere bulldozing their way toward  record highs Wednesday in reaction to the publication in the New England
4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize
The weekend was abuzz with rumors of U.K.
Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy
The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE:
Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B
AbbVie Shares Double In A Year; Leerink Moves To Sidelines
Plenty Of Opportunity In AbbVie, Even After Recent Run
43% Upside Seen For Dova Pharma Following Competitor Product's Poor Results
Biogen's Catalysts May Be Waning; Leerink Downgrades To Market Perform
Alexion's Drug Trial Miss Doesn't Change Analysts' Long-Term Thesis
Alexion's Valuation Could Be Getting Pummeled Unnecessarily
Vertex Pharmaceuticals' Phase 3 Studies Offer Ample Opportunity For Upside
Gilead's HCV Franchise Erosion Here To Stay; Leerink Cuts Price Target
Jury Rules Merck Patents Valid…Bad For Gilead?
3 Mega Biotechs Leerink Loves
Is Gilead Sciences About To Buy Vertex For $45 Billion?